ProCE Banner Activity

IFM2017-03: Phase III Trial of Daratumumab Plus Lenalidomide Without Long-term Dexamethasone vs Lenalidomide and Dexamethasone in Frail Patients With Newly Diagnosed MM

Conference Coverage
Slideset

Results from the phase III IFM2017-03 study demonstrated that a dexamethasone-sparing regimen with dara/len resulted in a significant PFS and OS benefit compared with standard len/dex treatment regimen in frail patients with newly diagnosed MM.

Released: December 12, 2024

Expiration: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation